DDMAC HOME PAGE WILL CARRY QUARTERLY REVIEW OF REGULATORY LETTER ISSUES; INDUSTRY SHOULD RETHINK AD PRECLEARANCE FOR LAUNCHES, J&J's PATTERSON SAYS
FDA's Division of Drug Marketing, Advertising and Communications Internet home page will contain a quarterly review of advertising regulatory actions, DDMAC Public Health Advisor Melissa Moncavage told a Food & Drug Law Institute meeting May 21 in Washington, D.C.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth